☆ 4.7 Article

Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3-or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial

CLINICAL INFECTIOUS DISEASES (2022)

Related references

Note: Only part of the references are listed.
Article Immunology

Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infection

Pedro Cahn et al.

Summary: The study assessed the efficacy and safety of dolutegravir lamivudine compared to dolutegravir with tenofovir disoproxil fumarate/emtricitabine in treatment-naive adults with HIV-1. The results showed that dolutegravir lamivudine was noninferior to dolutegravir with tenofovir disoproxil fumarate/emtricitabine in terms of virologic response. The dolutegravir lamivudine group had a lower rate of adverse events and less impact on renal and bone biomarkers. These findings support the use of dolutegravir lamivudine as a first-line treatment for HIV-1.

AIDS (2022)

Add to Collection
Review Infectious Diseases

Effectiveness and safety of dolutegravir two-drug regimens in virologically suppressed people living with HIV: a systematic literature review and meta-analysis of real-world evidence

Y. S. Punekar et al.

Summary: The study found that treatment with DTG + 3TC or DTG + RPV in clinical practice results in a low rate of virological failure and a high rate of virological suppression in people living with HIV-1 who have already achieved virological suppression.

HIV MEDICINE (2021)

Add to Collection
Review Infectious Diseases

HIV Treatment with the Two-Drug Regimen Dolutegravir Plus Lamivudine in Real-world Clinical Practice: A Systematic Literature Review

Rickesh Patel et al.

Summary: The two-drug regimen of dolutegravir plus lamivudine has shown durable efficacy for up to 3 years in phase III studies, demonstrating a high barrier to resistance in HIV patients. A systematic literature review of real-world evidence confirms high rates of virologic response and low rates of discontinuation in clinical practice, consistent with randomized controlled trial data.

INFECTIOUS DISEASES AND THERAPY (2021)

Add to Collection
Article Immunology

Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3-or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study

Jean van Wyk et al.

CLINICAL INFECTIOUS DISEASES (2020)

Add to Collection
Article Immunology

Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials

Pedro Cahn et al.

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2020)

Add to Collection
Review Medicine, General & Internal

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults 2020 Recommendations of the International Antiviral Society-USA Panel

Michael S. Saag et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection
Article Medicine, General & Internal

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

Pedro Cahn et al.

LANCET (2019)

Add to Collection
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.